Forty-eight cases of leiomyosarcoma of bone in Japan: A multicenter study from the Japanese musculoskeletal oncology group

Tomoaki Mori, Robert Nakayama, Makoto Endo, Hiroaki Hiraga, Masato Tomita, Naomasa Fukase, Eisuke Kobayashi, Akira Kawai, Takafumi Ueda, Hideo Morioka

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Leiomyosarcoma of bone (LMSoB) is a rare malignant bone tumor. This multicenter retrospective study was conducted to investigate the diagnosis and the clinical outcome of primary LMSoB in Japan. Methods: Forty-eight patients (average age: 52 years [range 14–88 years]) with primary LMSoB who were treated at registered institutes in Japan between 1991 and 2014 were recruited. The median follow-up period was 44 months (range: 2–273). Results: The 5-year overall survival rates and disease-free survival rates were 78.3% and 44.9%, respectively. Surgical treatment was performed in 42 patients, and R0 resection was achieved in 31 patients. Neoadjuvant chemotherapy was administered in 18 patients. The most common regimen (cisplatin-based chemotherapy) was administered in 15 patients, however, no patient achieved a good response in both radiological and histological evaluations. The presence of metastasis at the first visit and a lack of definitive surgery were significantly correlated with poor overall survival, and the surgical margin was a significant prognostic factor for disease-free survival. Conclusions: This study is the largest LMSoB case series ever reported. Surgical treatment with wide margins was the only treatment that proved to be effective, whereas adjuvant chemotherapy in the present setting did not improve the overall survival. J. Surg. Oncol. 2016;114:495–500.

Original languageEnglish
Pages (from-to)495-500
Number of pages6
JournalJournal of Surgical Oncology
Volume114
Issue number4
DOIs
Publication statusPublished - Sep 15 2016

Fingerprint

Leiomyosarcoma
Multicenter Studies
Japan
Bone and Bones
Disease-Free Survival
Survival Rate
Drug Therapy
Survival
Adjuvant Chemotherapy
Cisplatin
Therapeutics
Retrospective Studies
Neoplasm Metastasis
Neoplasms

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Forty-eight cases of leiomyosarcoma of bone in Japan : A multicenter study from the Japanese musculoskeletal oncology group. / Mori, Tomoaki; Nakayama, Robert; Endo, Makoto; Hiraga, Hiroaki; Tomita, Masato; Fukase, Naomasa; Kobayashi, Eisuke; Kawai, Akira; Ueda, Takafumi; Morioka, Hideo.

In: Journal of Surgical Oncology, Vol. 114, No. 4, 15.09.2016, p. 495-500.

Research output: Contribution to journalArticle

Mori, T, Nakayama, R, Endo, M, Hiraga, H, Tomita, M, Fukase, N, Kobayashi, E, Kawai, A, Ueda, T & Morioka, H 2016, 'Forty-eight cases of leiomyosarcoma of bone in Japan: A multicenter study from the Japanese musculoskeletal oncology group', Journal of Surgical Oncology, vol. 114, no. 4, pp. 495-500. https://doi.org/10.1002/jso.24322
Mori, Tomoaki ; Nakayama, Robert ; Endo, Makoto ; Hiraga, Hiroaki ; Tomita, Masato ; Fukase, Naomasa ; Kobayashi, Eisuke ; Kawai, Akira ; Ueda, Takafumi ; Morioka, Hideo. / Forty-eight cases of leiomyosarcoma of bone in Japan : A multicenter study from the Japanese musculoskeletal oncology group. In: Journal of Surgical Oncology. 2016 ; Vol. 114, No. 4. pp. 495-500.
@article{c66fd7e77a384207a785ffb9728c7024,
title = "Forty-eight cases of leiomyosarcoma of bone in Japan: A multicenter study from the Japanese musculoskeletal oncology group",
abstract = "Background: Leiomyosarcoma of bone (LMSoB) is a rare malignant bone tumor. This multicenter retrospective study was conducted to investigate the diagnosis and the clinical outcome of primary LMSoB in Japan. Methods: Forty-eight patients (average age: 52 years [range 14–88 years]) with primary LMSoB who were treated at registered institutes in Japan between 1991 and 2014 were recruited. The median follow-up period was 44 months (range: 2–273). Results: The 5-year overall survival rates and disease-free survival rates were 78.3{\%} and 44.9{\%}, respectively. Surgical treatment was performed in 42 patients, and R0 resection was achieved in 31 patients. Neoadjuvant chemotherapy was administered in 18 patients. The most common regimen (cisplatin-based chemotherapy) was administered in 15 patients, however, no patient achieved a good response in both radiological and histological evaluations. The presence of metastasis at the first visit and a lack of definitive surgery were significantly correlated with poor overall survival, and the surgical margin was a significant prognostic factor for disease-free survival. Conclusions: This study is the largest LMSoB case series ever reported. Surgical treatment with wide margins was the only treatment that proved to be effective, whereas adjuvant chemotherapy in the present setting did not improve the overall survival. J. Surg. Oncol. 2016;114:495–500.",
author = "Tomoaki Mori and Robert Nakayama and Makoto Endo and Hiroaki Hiraga and Masato Tomita and Naomasa Fukase and Eisuke Kobayashi and Akira Kawai and Takafumi Ueda and Hideo Morioka",
year = "2016",
month = "9",
day = "15",
doi = "10.1002/jso.24322",
language = "English",
volume = "114",
pages = "495--500",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Forty-eight cases of leiomyosarcoma of bone in Japan

T2 - A multicenter study from the Japanese musculoskeletal oncology group

AU - Mori, Tomoaki

AU - Nakayama, Robert

AU - Endo, Makoto

AU - Hiraga, Hiroaki

AU - Tomita, Masato

AU - Fukase, Naomasa

AU - Kobayashi, Eisuke

AU - Kawai, Akira

AU - Ueda, Takafumi

AU - Morioka, Hideo

PY - 2016/9/15

Y1 - 2016/9/15

N2 - Background: Leiomyosarcoma of bone (LMSoB) is a rare malignant bone tumor. This multicenter retrospective study was conducted to investigate the diagnosis and the clinical outcome of primary LMSoB in Japan. Methods: Forty-eight patients (average age: 52 years [range 14–88 years]) with primary LMSoB who were treated at registered institutes in Japan between 1991 and 2014 were recruited. The median follow-up period was 44 months (range: 2–273). Results: The 5-year overall survival rates and disease-free survival rates were 78.3% and 44.9%, respectively. Surgical treatment was performed in 42 patients, and R0 resection was achieved in 31 patients. Neoadjuvant chemotherapy was administered in 18 patients. The most common regimen (cisplatin-based chemotherapy) was administered in 15 patients, however, no patient achieved a good response in both radiological and histological evaluations. The presence of metastasis at the first visit and a lack of definitive surgery were significantly correlated with poor overall survival, and the surgical margin was a significant prognostic factor for disease-free survival. Conclusions: This study is the largest LMSoB case series ever reported. Surgical treatment with wide margins was the only treatment that proved to be effective, whereas adjuvant chemotherapy in the present setting did not improve the overall survival. J. Surg. Oncol. 2016;114:495–500.

AB - Background: Leiomyosarcoma of bone (LMSoB) is a rare malignant bone tumor. This multicenter retrospective study was conducted to investigate the diagnosis and the clinical outcome of primary LMSoB in Japan. Methods: Forty-eight patients (average age: 52 years [range 14–88 years]) with primary LMSoB who were treated at registered institutes in Japan between 1991 and 2014 were recruited. The median follow-up period was 44 months (range: 2–273). Results: The 5-year overall survival rates and disease-free survival rates were 78.3% and 44.9%, respectively. Surgical treatment was performed in 42 patients, and R0 resection was achieved in 31 patients. Neoadjuvant chemotherapy was administered in 18 patients. The most common regimen (cisplatin-based chemotherapy) was administered in 15 patients, however, no patient achieved a good response in both radiological and histological evaluations. The presence of metastasis at the first visit and a lack of definitive surgery were significantly correlated with poor overall survival, and the surgical margin was a significant prognostic factor for disease-free survival. Conclusions: This study is the largest LMSoB case series ever reported. Surgical treatment with wide margins was the only treatment that proved to be effective, whereas adjuvant chemotherapy in the present setting did not improve the overall survival. J. Surg. Oncol. 2016;114:495–500.

UR - http://www.scopus.com/inward/record.url?scp=84990232159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990232159&partnerID=8YFLogxK

U2 - 10.1002/jso.24322

DO - 10.1002/jso.24322

M3 - Article

C2 - 27302734

AN - SCOPUS:84990232159

VL - 114

SP - 495

EP - 500

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -